Chronic autoimmune urticaria in children

Srebrnjak Children's Hospital, Reference Center for Pediatric Allergology of the Ministry of Health and Social Welfare, Srebrnjak 100, HR-10000 Zagreb, Croatia.
Acta dermatovenerologica Croatica: ADC / Hrvatsko dermatolosko drustvo (Impact Factor: 0.43). 06/2008; 16(2):65-71.
Source: PubMed

ABSTRACT Results of determination of circulating histamine releasing autoantibodies using histamine release urticaria test in 12 children (aged 3 to 18 years, mean age 8.5 years; 7 female and 5 male) with chronic urticaria are presented. Standard work-up including detailed history, allergy testing and routine laboratory findings did not disclose any plausible cause of chronic/recurrent urticarial eruption in these children. All children underwent serum-induced basophil histamine release urticaria test. At serum dilution of 12.5%, the mean percent of histamine liberation was 40.8% (range 18%-77%; normal <16.5%), which indicated the presence of autoantibodies to Fc epsilon RI and/or to the IgE-Fc epsilon RI complex. The percent of histamine release did not correlate with patient age or duration and severity of symptoms. Thus the autoimmune basis of chronic urticaria was established. Associated antithyroid autoantibodies were found in two patients. Complete or partial remission was obtained with treatment that included antihistamines, low salicylate-low preservative diet in all, and high dose intravenous immunoglobulin in 3 children.

Download full-text


Available from: Slavica Dodig, Sep 28, 2015
38 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: It is well-recognized that 30-40% of chronic idiopathic urticaria is autoimmune in nature. Chronic autoimmune urticaria is caused by anti-FcepsilonRI and less frequently, by anti-IgE autoantibodies that lead to mast cell and basophil activation, thereby giving rise to the release of histamine and other proinflammatory mediators. Activation of the classical complement pathway and formation of C5a are important in dermal mast cell activation. C5a is also a neutrophil and eosinophil chemoattractant. Chronic autoimmune urticaria has been found to be associated with autoimmune thyroid disease. The autologous serum skin test is used as a screening test for chronic autoimmune urticaria and has a sensitivity and specificity of about 70 and 80%, respectively. The current gold standard diagnostic test is the basophil histamine release assay. The treatment of chronic autoimmune urticaria, as in chronic idiopathic urticaria, is with H1 antihistamines. Oral corticosteroids may be used during acute flares. Refractory cases have been shown to respond to cyclosporine and other immunomodulators. The prevalence of chronic autoimmune urticaria in Singapore is similar to that reported in Western countries at about 42%. The presence of thyroid autoimmunity appears to be higher than reported, with 22.5% of patients with chronic idiopathic urticaria here, exhibiting presence of thyroid autoantibodies.
    Indian Journal of Dermatology 07/2009; 54(3):269-74. DOI:10.4103/0019-5154.55640
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This book explains what the Feingold Diet does, who it can help, and the research supporting it.
    3 edited by Shula Edelkind, 01/2012; Self.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic urticaria (CU) in children is a distressful disorder which can often be challenging to treat. Elimination or treatment of eliciting stimulus is the first step in the management of CU; however, in majority of cases the cause remains unknown. According to currently available guidelines, H1-antihistamines are still the first line therapy for treatment of CU in children. Unfortunately, regularly approved doses relieve symptoms in less than 50% of patients, necessitating a dose increase for up to fourfold. However, even high dose of H1-antihistamines for some patients are unsatisfactory leaving a place for new therapeutic strategies in the treatment of CU; firstly to add either leukotriene antagonist or H2-antihistamine. For severe, nonresponsive cases other therapeutic approaches should be considered. However, it is important to be familiar with possible side-effects, because some of these approaches relate to the off-label use of drugs. This review presents summary of all available evidence in the treatment of CU in pediatric patients up to January 2012.
    Pediatric Allergy, Immunology, and Pulmonology 12/2012; 25(4). DOI:10.1089/ped.2012.0149 · 0.66 Impact Factor